Article Text

Download PDFPDF

756 First-in-human, open-label, multicenter, phase 1 clinical study to evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of anti Siglec-15 PYX-106 in subjects with advanced solid tumors
  1. Alexander I Spira1,
  2. Michael S Gordon2,
  3. Jason Henry3,
  4. Sandip P Patel4,
  5. Kartik Sehgal5,
  6. Shiraj Sen6,
  7. Randy Sweis7,
  8. Marsha Crochiere8,
  9. Shui He8,
  10. Sondra Smyrnios8,
  11. Dipali Unadkat8,
  12. Bin Zhang8 and
  13. Anthony W Tolcher9
  1. 1Virginia Cancer Specialists, Fairfax, VA, USA
  2. 2HonorHealth Research and Innovation Institute, Scottsdale, AZ, USA
  3. 3Sarah Cannon Research Institute at HealthONE, Denver, CO, USA
  4. 4University of California San Diego Moores Cancer Center, La Jolla, CA, USA
  5. 5Dana-Farber Cancer Institute, Boston, MA, USA
  6. 6NEXT Oncology – Dallas, San Antonio, TX, USA
  7. 7The University of Chicago, Chicago, IL, USA
  8. 8Pyxis Oncology, Boston, MA, USA
  9. 9NEXT Oncology, San Antonio, TX, USA
  • Journal for ImmunoTherapy of Cancer (JITC) preprint. The copyright holder for this preprint are the authors/funders, who have granted JITC permission to display the preprint. All rights reserved. No reuse allowed without permission.


Background Anti-programmed cell death-1 (PD-1)/PD ligand 1 (PD-L1) checkpoint blockade has not been effective for all solid tumors and alternative therapies are needed for patients who do not respond to currently approved checkpoint inhibitors. Sialic acid binding immunoglobulin like lectin-15 (Siglec-15) is an immunomodulatory pathway independent of PD-1/PD-L1. Siglec-15 is expressed on tumor cells and macrophages and has been shown to play a role in the inhibition of T cells. Blocking Siglec-15 overcomes T cell inhibition and limits tumor growth.

PYX-106 is an investigational, fully human, anti Siglec-15 immunoglobulin G1 kappa (IgG1k) monoclonal antibody that binds to human Siglec-15 with high affinity and cross-reacts to cynomolgus monkey, rat, and mouse Siglec-15. PYX-106 potently reverses Siglec-15-mediated suppression of CD4+ and CD8+ proliferation and induces IFN-gamma secretion in an ex vivo model. The PYX-106–101 clinical trial is in progress in participants with advanced cancers.

Methods PYX-106 is being evaluated in a first-in-human, open-label, non-randomized, Phase 1 dose-escalation (Part 1) study in participants with advanced solid tumors known to have expression of Siglec-15 (NCT05718557). The phase 1 study utilizes a Bayesian optimal interval design to explore ascending doses of PYX-106 administered as an intravenous infusion to identify the recommended phase 2 dose(s). The study is designed to characterize safety and pharmacokinetics and incorporates a robust translational biomarker plan. Upon completion of Part 1 and depending upon the data obtained, a Part 2 Dose Expansion part of the study may be initiated. The PYX-106–101 study began enrolling participants in February 2023 and will be conducted in the US and Europe. Adverse events are assessed according to National Cancer Institute Common Terminology Criteria for Adverse Events Version 5.0. Tumor response is determined according to Response Evaluation Criteria in Solid Tumors 1.1 criteria and safety findings are reviewed by the dose escalation steering committee, which monitors the safety and recommends dose(s) for Part 2. The study population includes participants with histologically or cytologically confirmed solid tumors including non-small cell lung cancer (without driver mutations/translocations), breast cancer, endometrial cancer, thyroid cancer, kidney cancer, cholangiocarcinoma, bladder cancer, colorectal cancer, and head and neck squamous cell carcinoma. Clinical Trial Information: NCT05718557

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.